VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps. The Food and Drug Administration (FDA ...
Please provide your email address to receive an email when new articles are posted on . Multiple small floaters were reported by one patient after pegcetacoplan injection. The authors reviewed the ...
As part of a patient-support program (PSP) for those with neuroendocrine tumors (NETs), Ipsen offers Somatuline Autogel/Somatuline Depot (lanreotide) in a prefilled syringe. The company recently ...
Fresenius Kabi announced today the U.S. introduction of Fentanyl Citrate Injection, USP 50 mcg per 1 mL in its proprietary Simplist (R) ready-to-administer prefilled syringe, the only 1 mL ...
Designed for contrast media injections, the PowrSyringe is capable of an injection that is between 20 and 100% faster than a standard control syringe. Nothing beats the need for speed when it comes to ...
Credit: Fresenius Kabi. The 100mcg per 2mL presentation is offered in a manufacturer-prepared prefilled syringe. Fresenius Kabi has launched a 100mcg per 2mL presentation of Fentanyl Citrate Injection ...
MIT researchers have developed a simple, low-cost technology to administer powerful drug formulations that are too viscous to be injected using conventional medical syringes. The technology, which is ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results